SO-31: Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset

Abstract Presenter(s)

• 

  Elena Garralda, MD

  Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology
  Barcelona, Spain